Compare SIRI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIRI | NUVL |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.3B |
| IPO Year | 1996 | 2021 |
| Metric | SIRI | NUVL |
|---|---|---|
| Price | $28.77 | $101.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $28.86 | ★ $134.75 |
| AVG Volume (30 Days) | ★ 4.8M | 469.5K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 136.32 | N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $5,425,129,000.00 | N/A |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $0.67 | $1,239.49 |
| P/E Ratio | $12.98 | ★ N/A |
| Revenue Growth | ★ 8.13 | N/A |
| 52 Week Low | $19.77 | $70.25 |
| 52 Week High | $29.24 | $113.02 |
| Indicator | SIRI | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 68.50 | 47.79 |
| Support Level | $20.35 | $97.91 |
| Resistance Level | N/A | $107.72 |
| Average True Range (ATR) | 0.82 | 3.83 |
| MACD | 0.10 | -0.24 |
| Stochastic Oscillator | 79.99 | 29.93 |
SiriusXM operates almost exclusively in the US through its SiriusXM and Pandora audio services. SiriusXM is primarily a satellite radio service that offers nationwide coverage and mostly ad-free listening, with proprietary channels and exclusive content. It makes agreements with automakers to install its radios in vehicles and give trial services to vehicle buyers, which have traditionally fed its subscriber base. The company provides the service via a fleet of geostationary satellites it owns and operates, and now offers a streaming SiriusXM option. Pandora, which accounts for a much smaller portion of revenue and profit, offers a subscription and ad-supported streaming music service that competes with industry giants such as Spotify, Apple Music, and YouTube Music.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.